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Abstract
Background: Recently, continuous administration of piperacillin-tazobactam has been proposed as a valuable
alternative to traditional intermittent administration especially in critically ill patients. However, antibiotic dosing
remains a challenge for clinicians as antibiotic dosing regimens are usually determined in non-critically ill
hospitalized adult patients. The aim was to conduct a systematic review to identify and highlight studies comparing
clinical outcomes of piperacillin tazobactam dosing regimens, continuous/prolonged infusion vs intermittent
infusion in critically ill patients. Meta-analyses were performed to assess the overall effect of dosing regimen on
clinical efficacy.
Methods: Studies were identified systematically through searches of PubMed and Science Direct, in compliance
with PRISMA guidelines. Following the systematic literature review, meta-analyses were performed using Review
Manager.
Results: Twenty-three studies were included in the analysis involving 3828 critically ill adult participants in total
(continuous/prolonged infusion = 2197 and intermittent infusion = 1631) from geographically diverse regions.
Continuous/prolonged resulted in significantly: higher clinical cure rates (Odds Ratio 1.56, 95% Confidence Interval
1.28–1.90, P = 0 .0001), lower mortality rates (Odds Ratio 0.68, 95% Confidence Interval 0.55–0.84, P = 0 .0003), higher
microbiological success rates (Odds Ratio 1.52, 95% Confidence Interval 1.10–2.11, P = 0.01) and decreasing the
length of hospital stay (Mean Difference − 1.27, 95% Confidence Interval − 2.45—0.08, P = 0.04) in critically ill
patients.
Conclusion: Results from this study show that there is a significant level of evidence that clinical outcome in
critically ill patients is improved in patients receiving piperacillin-tazobactam via continuous/prolonged infusion.
However, more rigorous scientific studies in critically ill patients are warranted to reach a sufficient level of evidence
and promote further implementation of C/PI as a dosing strategy.
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Background
Recently, continuous administration of piperacillin-
tazobactam has been proposed as a valuable alterna-
tive to traditional intermittent administration
especially in critically ill patients. However, correct
antibiotic dosing remains a challenge for clinicians as
antibiotic dosing regimens are usually determined in
non-critically ill hospitalized adult patients. Patient
that are in intensive care units (ICU) differ from
other hospitalized patients in terms of pathophysi-
ology and disease severity; these factors not only
affect metabolism but also drug pharmacokinetics/
pharmacodynamics (PK/PD) behaviour. Critically ill
patients also have an increased risk (5–10 times more
likely) of having or developing infections and infec-
tious complications than those in general wards [1].
Dosing strategies that have been validated in patient
populations that are non-critically ill fail to consider the
substantial changes in organ function that occur with
critical illness [2]. Augmented renal clearance of antibi-
otics is increasingly reported in critically ill patients.
Antibiotic dosing concentrations will vary greatly within
intensive care patients with normal kidney function or
renal failure as the pharmacokinetic target attainment is
dependent on kidney function [3]. Given the enhanced
renal elimination reported in critically ill patients, anti-
microbial dosing requires extensive consideration due to
important clinical consequences as accurate and timely
drug exposure is essential for clinical success. The aug-
mented renal clearance is possibly associated with the
(1) immune response to infection, (2) inflammation to
fluid loading and, (3) use of vasoactive medications. An
increase in both cardiac output and blood flow is there-
fore observed, leading to enhanced glomerular filtration
that results in sub-therapeutic piperacillin-tazobactam
concentrations due to substantial drug elimination [4].
The optimisation of antimicrobial agents is a relatively
unexplored area where further research is needed. Con-
tinuous infusions (CI) and prolonged infusions (PI) of
piperacillin-tazobactam has been directly linked to im-
proved clinical outcome displaying capabilities such as
lowering the possibility of resistance and decreasing
mortality [2, 5, 6]. The aim here is to systematically re-
view the literature comparing the clinical outcome of pi-
peracillin tazobactam dosing regimens, continuous/
prolonged infusion C/PI and II.
Methods
Literature search
A systematic review of the literature was conducted [7–10];
references published between 1998 and 2019 were ac-
knowledged through searches on PubMed and Science Dir-
ect, in compliance with PRISMA guidelines. Search terms
used were: (penicillin OR penicillins OR piperacillin OR
tazobactam OR piperacillin-tazobactam OR piperacillin/
tazobactam) AND (intermittent OR bolus OR short OR
prolonged OR extended OR continuous) AND (infusion
OR duration OR administration OR interval OR dosing)
AND (intensive care OR ICU OR critically ill OR critical
care OR septic shock OR sepsis OR severe sepsis).
However, like any database, their coverage is not
complete, therefore the authors retrieved additional arti-
cles using supplementary approaches such as manual
searching of journals, Google Scholar and checking ref-
erence lists of articles to identify additional text. A full
review of published studies was implemented addressing
and comparing clinical outcome of IV piperacillin-
tazobactam dosing regimens administered to infected
critically ill patients. The last search was on the 1st of
August 2019 [PROSPERO registration number:
CRD42019117303].
Study selection
Initially, all articles reporting comparative outcomes
of critically ill patients treated with C/PI versus II
piperacillin-tazobactam were considered eligible. The
eligibility criteria were separated into two compo-
nents: study characteristics and report characteristics.
Study eligibility criteria included the types of a) stud-
ies, b) participants, c) interventions and d) outcome
measures; these measures are presented in Table 1.
Report eligibility criteria included: publications written
in English language, study status is “published” and
inclusion of both old and new data. Exclusion criteria
included: Pharmacoeconomic studies, non-human sub-
jects, non-adult subjects, non-critically ill subjects,
non-English language studies and pilot studies. Sys-
tematic reviews, meta-analysis and editorials were also
excluded.
Table 1 Showing eligibility criteria for study selection process
Eligibility Criteria
a) Studies Prospective and retrospective trials/studies
comparing/evaluating clinical efficacy or clinical
outcome of piperacillin/tazobactam administered via
CI vs II in critically ill patients. Pilot studies excluded
b) Participants Critically ill adult participants aged 18 and over
suffering from documented bacterial infection and
requiring treatment with piperacillin-tazobactam.
Non-adult, non-human and non-critically ill patient
studies were excluded.
c) Interventions Studies comparing the beneficial and harmful/limiting
effects of CI and II. Infusions of all types (CI, PI and II),
dose and regimen are adequate for the review.
Pharmacoeconomic studies were also excluded.
d) Outcome
measures
All studies were eligible if specifically related to
clinical outcome/efficacy of dosing regimens. All
outcomes were included to reduce risk of bias as a
consequence of selective reporting.
CI Continuous infusion, II Intermittent infusion
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Data analysis
A data extraction form was developed based on
Cochrane data extraction template. The information ex-
tracted from each of the included studies consisted of:
1. Characteristics of participants (didn’t necessarily
comprise characteristics such as age and sex
however, includes characteristics such as the disease
patient is diagnosed with and the method of
diagnosis) and the eligibility criteria (inclusion and
exclusion measures);
2. The type of intervention – mode of administration,
continuous vs intermittent dosing (including the
drug, dose, duration of infusion and frequency);
3. Type of outcome measure (including clinical
outcome and clinical efficacy in terms of clinical
cure).
One reviewer extracted the following data from in-
cluded studies (S.F); the second and third reviewers veri-
fied the relevance of the extracted information (S.N-G
and S.B). Variances in opinions were resolved by discus-
sion between the three reviewers.
Risk of Bias and study quality assessment
Methodological assessment of included RCTs was
undertaken using the Cochrane risk of bias tool. Two re-
viewers individually assessed the risk of bias (S.F and
S.N-G) with disagreements resolved by a third reviewer
(S.B). Six domains of bias were assessed including: (1)
random sequence generation, (2) allocation conceal-
ment, (3) blinding of participants and personnel, (4) in-
complete outcome data, (5) selective reporting and (6)
other biases. Publication bias was evaluated using funnel
plots.
The methodological quality of included RCT’s was
assessed with the Jadad Scale [11] that evaluated the tri-
al’s randomisation, double blinding and reports of with-
drawals and dropouts. An overall score of 0–5 points
was assigned, where an overall score of three and above
was regarded as adequate trial quality.
The Newcastle-Ottawa Scale is a quality assessment
tool for selection, comparability and outcome assess-
ment used to assess the quality of included observational
studies (retrospective and prospective) [12]. Studies scor-
ing more than six stars are considered as being good
quality.
No studies were excluded on the basis of quality as-
sessment however their quality scores were taken into
account when describing results.
Statistical analysis
Meta-analysis was performed using Review Manager for
Windows Version 5.3 to compare the clinical efficacy of
C/PI vs II in terms of clinical cure, mortality, microbio-
logical cure rates, adverse events and length of hospital
stay. Pooled odds ratio (OR) and 95% confidence inter-
vals (C.I) were calculated for dichotomous data, taking
into account all outcomes from included studies. Pooled
mean difference (MD) and 95% C.I were calculated for
continuous data. Statistical heterogeneity was assessed
by employing χ2 test and I2 statistic. The presence of
heterogeneity between studies was assessed by χ2 test
(P < 0.10 indicates significant heterogeneity) and the ex-
tent of the inconsistencies was considered using I2 statis-
tic (I2 > 70% indicates considerable heterogeneity). The
pooled outcomes were calculated using Mantel-Haenszel
fixed effect model when there was no significant hetero-
geneity otherwise the random effects model was chosen.
‘Emergence of resistance’ was narratively reviewed in-
stead of statistical analysis considering the few sample
sizes included.
Results
Search results
The search of PubMed and Science Direct provided 199
citations. Of these, 154 studies were excluded following
review of the abstracts, as they did not meet the inclu-
sion criteria. Twenty articles were discarded after
reviewing the full article due to the following reasons:
non-human (n = 2), on non-critically ill (n = 10) and chil-
dren (n = 8) subjects. A further four studies were elimi-
nated due to the focus being on pharmacoeconomics
and renal replacement therapy.
An additional two studies that met the inclusion cri-
teria were acknowledged through checking references of
relevant studies. Twenty-three studies met the described
inclusion criteria and were included in the systematic re-
view [13–34]. The article selection process is illustrated
in Fig. 1 and selected studies comparing clinical out-
come between CI and II of piperacillin are listed in
Table 2. Characteristics of included studies comprising
of demographic characteristics, C/PI and II dosage, drug
regimen treatment results as well as study outcomes and
suggestions were extracted from all studies and sum-
marised (Table 2). Out of the twenty-three studies in-
cluded, only an abstract (and no full article) could be
obtained for four of the studies [19, 20, 25, 26].
Definitions
‘Clinical cure’ was defined as ‘the complete resolution of
clinical signs and symptoms of infection, with no new
signs or symptoms associated with the original infection’
[32, 36].
‘Microbiological cure’ was defined as ‘the eradication
and presumed eradication of organisms at the infection
site’ [36].
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‘Adverse events’ were defined as ‘any unexpected med-
ical occurrences in patients administered piperacillin-
tazobactam caused by either the drug or dosing regimen
being received’ [36].
Study characteristics
The type of studies included in the systematic review
and meta-analysis were RCT’s (n = 10), observational co-
hort studies (n = 12; retrospective n = 10, prospective
n = 2) and a Quasi-experimental study (non-randomised
trial) (n = 1).
Study quality
The quality of the majority of RCT’s included was mod-
erate to high (Table 3). According to the Jadad scale,
seven out of ten RCT’s (70%) obtained a score of three
and above. The studies by Ye [20] and Lu [26] had a
score of one and two respectively due to retrieval of only
the abstract (full text unavailable). Rafati [15] received a
score of two as the article did not describe randomisa-
tion method and study was not blinded. All observa-
tional studies assessed using the Newcastle Ottawa Scale
scored eight or nine stars and recognised as being of
high quality (Table 4).
Meta-analysis of included studies
Clinical cure
Seventeen of the included studies reported clinical cure
rates (Table 2) [6, 13–15, 18–21, 23, 24, 26–29, 31–33].
Patients that received C/PI had a statistically signifi-
cantly higher clinical cure rate compared to those who
received treatment via II (2535 patients; OR 1.56, 95%
C.I 1.28–1.90, P = 0 .0001; Fig. 2). No significant hetero-
geneity was found among the studies (I2 = 41%, P = 0.04).
The symmetrical funnel plot obtained indicates the ab-
sence of publication bias (Fig. 3).
Despite methodological differences among selected stud-
ies, patients receiving C/PI displayed higher clinical cure
rates compared with patients receiving II; overall, clinical
cure rate was 79.62 and 69.26% for C/PI and II respectively.
Pooling results from the 17 studies that reported clinical
cure showed that the odds of clinical cure was higher in pa-
tients receiving C/PI. The pooled OR shows that C/PI
piperacillin-tazobactam was 1.56 (95% C.I 1.28–1.90, P = 0
.0001), indicating clinical cure rates are 34% higher than in
II with the true population effect between 72 and 10%.
Mortality
Eighteen of the included studies reported patient mortal-
ity rates (Table 2) [13–18, 20, 21, 24, 27–34, 37].
Fig. 1 Flow diagram illustrating the selection process for included studies
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Statistically significantly fewer mortality rates were
found among patients receiving C/PI compared with pa-
tients receiving conventional II (3100 patients; OR 0.68,
95% C.I 0.55–0.84, P = 0 .0003; Fig. 4). No significant
heterogeneity was found among the studies (I2 = 0%, P =
0.56). The symmetrical funnel plot obtained indicates
the low possibility of publication bias (Fig. 5).
Results obtained from meta-analysis suggested that C/
PI piperacillin-tazobactam resulted in significantly lower
mortality rates. Overall, ICU mortality rate was 12.46
and 18.13% for C/PI and II respectively. Combining re-
sults from 18 studies that reported mortality, the pooled
OR shows that C/PI piperacillin-tazobactam was 0.68
(95% C.I 0.55–0.84), indicating lower mortality rates
compared with conventional II. This was statistically sig-
nificant (P = 0.0003) with the true population effect be-
tween 84 and 55%.
Microbiological cure
Seven of the included studies reported microbiological
cure rates [13, 14, 19, 20, 23, 27, 33]. Lau et al. [14] found
no statistically significant difference between the dosing
regimens however, higher microbiological success was
seen in patients receiving II. In contrast, Abdul-Aziz et al.
[33] found C/PI piperacillin-tazobactam had significantly
higher microbiological cure rates compared with II. Pool-
ing of the outcomes of seven studies that reported micro-
biological cure rates showed that patients receiving C/PI
had significantly higher microbiological success rates (920
patients; OR 1.52, 95% C.I 1.10–2.11, P = 0.01; Fig. 6). No
significant heterogeneity was found among studies (I2 =
0%, P = 0.48). The symmetrical funnel plot obtained dem-
onstrates the absence of publication bias (Fig. 7).
The pooled OR shows that C/PI piperacillin-
tazobactam was 1.52 (95% C.I 1.10–2.11), indicating C/
PI piperacillin-tazobactam achieved higher microbio-
logical cure rates compared to conventional II. Overall,
microbiological cure rates were 74.83 and 61.89% for C/
PI and II respectively. This was statistically significant
(P = 0.01).
Adverse events
Six of the included studies reported adverse events [13,
14, 31–34]. Participants enrolled in three of these studies
Table 3 Quality assessment of randomised control trials in meta-analysis based on the Jadad Scale
Quality assessment of RCT’s Lau [14] Rafati [15] Robert [17] Li [19] Ye [20] Lu [26] Jamal [28] Abdul [33] Cotrina [29] Bao [32]
2006 2006 2009 2010 2011 2013 2015 2016 2016 2017
(1) Described as randomised 1 1 1 1 1 1 1 1 1 1
(2) Described as double blind 0 0 0 0 0 0 0 0 1 0
(3) Description of withdrawals 1 1 1 1 0 1 1 1 1 1
(4) Randomisation method described 1 0 1 1 0 0 1 1 1 1
(5) Double blinding method described 0 0 0 0 0 0 0 0 1 0
Score (−/5) 3/5 2/5 3/5 3/5 1/5 2/5 3/5 3/5 5/5 3/5
RCT’s Randomised Control Trials
Randomisation:
Up to two points are given(1): described as randomised (yes = 1) (no = 0) and(4) randomisation method described (yes = 1) (no = 0)
Double blinding:
Up to two points are given(2): described as double blind (yes = 1) (no = 0) and(5) double blinding method described (yes = 1) (no = 0)
Reports of withdrawals and dropouts:
Up to one point is given(3): Description of withdrawals (yes = 1) (no = 0)
Table 4 Quality assessment of observational studies based on
the Newcastle-Ottawa Scale
Study Selection Comparability Outcome Score
A B C D E F G H
Grant 2002 [13] (p) * * * * ** * * * 9*
Lodise 2007 [16] (R) * * * * ** * * * 9*
Lorente 2009 [18] (R) * * * * ** * * * 9*
Rose 2011 [35] (R) * * * * ** * * * 9*
Yost 2011 [21] (R) * * * * * * * * 8*
Pereira 2012 [23] (R) * * * * ** * * * 9*
Lee 2012 [24] (R) * * * * ** – * * 8*
Waxier 2012 [25] (R) * * * * ** – * * 8*
Cutro 2014 [27] (R) * * * * * * * * 8*
Schmees 2016 [31] (R) * * * * ** – * * 8*
Winstead 2016 [30] (R) * * * * ** – * * 8*
Fan 2017 [34] (P) * * * * ** – * * 8*
(P) = prospective cohort study and (R) = retrospective cohort study
Selection:
A: representation of the exposed cohort (yes = *) (no = −), B: selection of non-
exposed cohort (yes = *) (no = −), C: ascertainment of exposure (yes = *) (no = −),
D: demonstration that outcome of interest was not present at start of study
(yes = *) (no = −)
Comparability:
E: comparability of cohorts on the basis of the design or analysis [controls for:
age, sex and marital status (yes = *) (no = −) and for other factors
(yes = *) (no = −)]
Outcome:
F: assessment of outcome (yes = *) (no = −), G: was follow up long enough for
outcome to occur (yes = *) (no = −) and H: adequacy of follow up of cohorts
(yes = *) (no = −).
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experienced adverse event [14, 31, 32]. Lau et al’s [14],
Bao et al. [32] and Schmees et al. [31] observed
treatment-related adverse events in patients receiving
both C/PI and II; CI: 16.9% vs II:13.6%, CI: 47.5% vs II:
53.8%, CI: 76% vs II:92%, respectively. Boa [32] reported
serious adverse events in 9 patients (PI:5 vs II:4), includ-
ing renal failure, Tachycardia and confusion.
The average occurrence of adverse events was 13.3%
for C/PI and 13.4% for II, respectively. Participants in
the other three studies did not experience adverse events
[13, 33, 34]. Data obtained from studies showed no sig-
nificant difference between the two infusion strategies
(935 patients; OR 0.85, 95% C.I 0.50–1.42, P = 0.53;
Fig. 8). No significant heterogeneity was found among
studies (I2 = 25%, P = 0.26).
Although adverse events were not observed in the
study by Grants et al. [13], dosing and administrative er-
rors arose where one patient was administered 13.5 g
piperacillin-tazobactam dose over a 30 min II rather than
a 24-h CI. Cortina et al. [29] reported that the most
common side effects experienced by patients were
gastrointestinal and allergic reactions but the number of
patients that experienced these was not reported. The
meta-analysis demonstrated that no adverse events that
are directly associated to the dosing regimens occurred.
C/PI resulted in a lower percentage of adverse events
Fig. 2 Forest plot representing the odds ratio of clinically cured patients from the C/PI and II patients in included studies
Fig. 3 Forest plot representing the odds ratio of mortality patients from C/PI and II patients in included studies
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however, the difference between the two groups did not
reach statistical significance (935 patients; OR 0.85, 95%
C.I 0.50–1.42, P = 0.53; Fig. 8).
Length of hospital stay
Fifteen of the included studies reported length of hos-
pital stay [13–16, 18, 23, 24, 26, 29–31, 33–35, 38]. Pool-
ing of studies showed that patients receiving C/PI had a
significantly shorter length of hospital stay (2101 pa-
tients; Mean Difference − 1.27, 95% C.I -2.45—0.08, P =
0.04; Fig. 9) The meta-analysis suggests there is a signifi-
cant reduction in the length of hospital stay in patients
receiving C/PI compared to those receiving II. Moderate
heterogeneity among studies evaluating ‘length of hos-
pital stay’ (I2 = 65%, P = 0.0003) was observed. This is
likely due to clinical heterogeneity in the design and out-
comes of the included studies. The length of hospital
stay was an independent risk factor for mortality, how-
ever the influence of mortality on the length of hospital
stay could not be evaluated.
Fig. 4 Symmetric funnel plot indicating the absence of publication bias in terms of clinical cure
Fig. 5 Symmetric funnel plot indicating the absence of publication bias in terms of patient mortality
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Emergence of resistance
Data regarding the emergence of resistance was reported
in four of the included studies [13, 14, 17, 18]. Two re-
sistant pathogens were isolated in one study [13] how-
ever, resistant strains were not isolated in three studies
[14, 17, 18] following the initiation of piperacillin-
tazobactam treatment. Three studies reported that no
resistant pathogen was isolated following the initiation
of piperacillin-tazobactam treatment. In the study con-
ducted by Grant et al. [13], two resistant strains were
isolated from patients receiving CI piperacillin-
tazobactam.
Risk of Bias
The majority of RCT’s and prospective studies assessed
were judged to have a low risk of bias for random se-
quence generation, allocation concealment, incomplete
outcome data, selective reporting and other biases. How-
ever, evaluations of blinding of participants and
personnel parameter was judged to have a high or un-
clear risk of bias (Fig. 10).
Discussion
To the best of our knowledge, this systematic review and
meta-analysis is the largest study describing clinical out-
comes of severely ill patients treated with either C/PI or
II piperacillin-tazobactam. The selected studies involved
3828 critically ill adult participants in total (C/PI = 2197
and II = 1631) from geographically diverse regions.
It is the first meta-analysis that shows C/PI resulted in
significantly: (1) higher clinical cure rates (2) lower mor-
tality rates (3) higher microbiological success rates and
(4) decreasing the length of hospital stay specifically in
critically ill patients. In all the studies, the primary
Fig. 6 Forest plot representing the odds ratio of microbiologically cured patients from the C/PI and II patients in included studies
Fig. 7 Symmetric funnel plot indicating the absence of publication bias in terms of microbiological cure
Fawaz et al. BMC Infectious Diseases          (2020) 20:430 Page 11 of 16
outcome assessed was clinical efficacy. The current study
differs from previously published systematic reviews and
meta-analyses [4, 36, 39–44] as it specifically focuses on
use of piperacillin-tazobactam in critically ill ICU pa-
tients. The present systematic review and meta-analysis
identified a significant clinical cure, mortality, microbio-
logical cure and length of hospital stay benefit for C/PI
across all included studies.
In theory, C/PI of piperacillin-tazobactam is a broadly
recognised strategy to optimize antibiotic therapy, where
concentrations remain above the MIC for a higher
percentage of time. Studies have demonstrated that the
amount of time in which the free or non-protein bound
antibiotic concentration exceeds the MIC (fT >MIC) of
the organism is the best predictor of clinical and micro-
biologic response for β-lactams [45, 46]. However, data
to backup this developing practice have been sparse [43].
Twenty-three published studies comparing C/PI and II
of piperacillin-tazobactam fit the inclusion criteria
(Table 2).
Outcomes of the current study correlate and expand
upon previously published reviews including several
Fig. 8 Forest plot representing the MD of length of hospital stay in C/PI and II groups in included studies
Fig. 9 Forest plot representing the odds ratio of adverse events experienced by patients from the C/PI and II groups in included studies
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analyses comparing clinical efficacy of dosing regimens
for beta-lactams generally [39–42]. These studies
pointed towards a more favourable outcome of C/PI for
improved clinical cure and resolution of illness. Falagas
et al. 2013 [40] and Vardakas el al 2018 reviewed out-
comes of C/PI and II beta-lactams. There was a signifi-
cant reduction in mortality rates among patients
receiving C/PI in both studies. Roberts et al. 2016 [42]
observed higher clinical rates and reduced mortality in
C/PI patients and Lal et al. 2016 [39] found C/PI to re-
duce clinical failure rates.
Finding in this study are consistent with published re-
views focused specifically on piperacillin-tazobactam [4,
36, 43, 44]. Yusuf el at 2014 [4] reviewed literature com-
paring the effectiveness of C/PI and II administration of
piperacillin-tazobactam. They documented C/PI im-
proved clinical cure, mortality and length of hospital stay
in comparison to II. Yang et al. 2015/6 [36, 44] observed
similar beneficial effects of C/PI in their systematic re-
views. Recently, Rhodes et al. 2017 [43] evaluated a wide
range of severely ill patients, from hospitalised patients
to critically ill patients admitted to ICU. C/PI
piperacillin-tazobactam is associated with improved clin-
ical outcome and significantly reduced mortality rates.
Several observations were encountered from reviewing
this data which led to reduced comparability among
Fig. 10 a Risk of bias summary of included RCT’s: displaying details about each risk of bias item for each trial. Green (+) indicates ‘low risk’, red
(−) indicates ‘high risk’ and yellow (?) indicates ‘unclear risk’. b Risk of bias assessment displaying judgements about each risk of bias item
presented as percentages across all RCT’s
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studies. First, clinical heterogeneity was present as se-
lected studies comparing C/PI and II in terms of clinical
outcomes have confounding factors including patient
sample size, study settings, study design, quality, inter-
vention and outcomes. Second, information regarding
monotherapy and combination antibiotic therapy were
not reported in the included studies. This reduces the
validity of conclusions on C/PI, as agents used possess
different antimicrobial spectrum, and drug-drug interac-
tions were unknown hence not considered. Third, asses-
sing safety was challenging due to under-reporting of
adverse events. Higher serum concentrations in C/PI pa-
tients over a longer period could potentially result in an
increased number of adverse events. Fourth, a large
number of included studies were RCT’s (10/23; 43.5%)
with small sample size. Small sample size may result in
bias and the probability of small study effects contribut-
ing to the favourable outcome for C/PI. However, meta-
analyses including small and large studies did not indi-
cate significant discrepancies and similar outcomes were
observed with fixed and random effect models. Fifth,
duration of piperacillin-tazobactam administration and
dosing is not homogenised between studies. CI was ad-
ministered over the entire dosing interval and the dur-
ation of a PI between studies ranged between 3 and 4 h
which is in line with proposed guidelines (2–4 h). Trad-
itional II durations between studies ranged between 20
and 30 min (usually 30–60min) [47]. Heterogeneity of
dosing was also noted. In 7/23 studies piperacillin-
tazobactam treatment was initiated with a loading dose
to ensure rapid achievement of therapeutic concentra-
tions. Also, the total daily dose administered differed be-
tween CI, PI and II, providing an additional confounding
factor as to whether the duration of infusion or total
daily dose attributed to clinical outcome (Table 2). Fi-
nally, it wasn’t apparent how critically ill the patients
within studies were as only four studies reported SOFA
scores.
Findings of this meta-analysis should be interpreted in
view of certain limitations. First, throughout this review,
PI and CI were combined and referred to as C/PI, thus,
it is unclear which of the two dosing strategies is most
effective for critically ill patients. Additionally, all studies
were evaluated for quality and risk of bias and based on
the overall assessment of these two factors no studies
were excluded (Tables 3, 4 and Fig. 10). Also, a medical
librarian was not involved in this study.
Conclusion
In conclusion, C/PI of piperacillin-tazobactam in critic-
ally ill patients was associated with (1) higher clinical
cure rates (2) lower mortality rates, (3) higher microbio-
logical success rates and, (4) decreasing the length of
hospital stay in critically ill ICU patients. No reduction
in ‘adverse events’ and ‘emergence of resistance’ has
been demonstrated. Results obtained in this study show
that clinical outcome in critically ill patients is signifi-
cantly better in those receiving C/PI. However, the su-
periority of the benefits and outcome gains achieved
with C/PI administration in comparison to II is difficult
to deduce as studies selected show considerable hetero-
geneity in terms of: (1) type of isolated bacteria, (2)
piperacillin-tazobactam dose, (3) MIC of pathogen, (4)
patient renal function, (5) duration of hospital stay and
(6) outcome definitions. More rigorous scientific studies
in critically ill patients are warranted to reach a suffi-
cient level of evidence to promote the widespread adop-
tion and further implementation of C/PI piperacillin-
tazobactam.
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